Clinical trials: Severe Community-acquired Pneumonia (sCAP)
Severe Community-acquired Pneumonia (sCAP)
Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)
Severe community-acquired pneumonia (sCAP) has a high mortality rate of 25-50%. Excessive host inflammatory responses contribute to poor outcomes.
- Trial name
- PANDA-SCAP (NCT07152587)
- Testing
- Low dose steroids, Moderate dose steroids, Saline (0.9% NaCl)
- Volunteers
- 1,500 people
- Sponsor
- Qingyuan Zhan
Sepsis, Severe Community-acquired Pneumonia (sCAP)
Molecular Biomarkers for Sepsis
This multi-center observational case-control study in Intensive Care Unit (ICU) patients is to identify novel biomarkers allowing to recognize severe community acquired pneumonia (sCAP) -associated sepsis at an earlier stage and…
- Conditions
- Sepsis, Severe Community-acquired Pneumonia (sCAP), Infection, Bacterial
- Trial name
- NCT04280354
- Testing
- compare data patterns by data-driven algorithms to determine sepsis, compare data patterns by data-driven algorithms to predict sepsis-related mortality
- Where
- 15 sites in Switzerland
- Volunteers
- 3 people
- Sponsor
- University Hospital, Basel, Switzerland
Community-acquired Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in hospitalized subjects with sCAP on invasive mechanical…
- Trial name
- ESsCAPE (NCT05722938)
- Testing
- Trimodulin
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 590 people
- Sponsor
- Biotest
Severe Community-acquired Pneumonia (sCAP)
Epidemiology and Current Practices in Severe Community-Acquired Pneumonia
The goal of this observational study is to learn more about severe community-acquired pneumonia (sCAP) in adults who need hospital or intensive care.
- Trial name
- PLENITUDE (NCT07301099)
- Where
- Colombia
- Volunteers
- 2,588 people
- Sponsor
- Universidad de la Sabana
Community Acquired Pneumonia
Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP
The purpose of this study is to determine whether the adjunctive therapy to standard antibiotic treatment of BT086 is safe and effective of decreasing the days patients require endotracheal ventilation due to Severe…
- Trial name
- CIGMA (NCT01420744)
- Testing
- BT086, 1% Human Albumin infusion
- Where
- 36 sites in Belgium, Germany and 2 more
- Volunteers
- 160 people
- Sponsor
- Biotest
Community Aquired Pneumonia
Study to Evaluate Two Diagnostic Strategies for the Treatment of Severe Community Acquired Pneumonia (SCAP)
Main hypothesis: microbiological diagnossis off severe community acquired pneumonia can be performed by non invasive or semi invasive microbiological tools, semi invasive tools including protected distal bronchial samplings by…
- Trial name
- NCT00308659
- Testing
- FOB protected distal microbiological samplings
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Community-acquired Pneumonia
A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
A Phase 1b/2a, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma gelsolin (rhu-pGSN) Added to Standard of Care in Subjects…
- Trial name
- NCT03466073
- Testing
- Recombinant Human Plasma Gelsolin
- Where
- 8 sites in Australia, Georgia
- Volunteers
- 33 people
- Sponsor
- BioAegis Therapeutics Inc.
Severe Community-acquired Pneumonia (sCAP)
Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea
This study aims to provide high-level evidence for appropriate empirical antibiotic use tailored to the clinical reality in Korea by conducting a randomized controlled trial comparing monotherapy with piperacillin/tazobactam and…
- Trial name
- ACTSCAP (NCT06977347)
- Testing
- Piperacillin/Tazobactam, Piperacillin/tazobactam + Levofloxacin
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- CHOSEOK YOON
Severe Community-Acquired Pneumonia (sCAP), Elderly Infection
ESCAPE10: Epidemiology, Risk Factors, and Outcomes of Severe Community-acquired Pneumonia in Elderly Patients Acquired Pneumonia in Elderly Patients
The ESCAPE 10 study is a multinational, retrospective, observational cohort study that aims to investigate the epidemiology and outcome determinants of severe community-acquired pneumonia (sCAP) in elderly patients (≥65 years).
- Conditions
- Severe Community-Acquired Pneumonia (sCAP), Elderly Infection, Community-Acquired Infections, Health Care Quality, Access, and Evaluation
- Trial name
- ESCAPE10 (NCT07070284)
- Where
- 18 sites in Croatia, France and 4 more
- Volunteers
- 500 people
- Sponsor
- Joan Sabater-Riera